Document Detail


Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
MedLine Citation:
PMID:  21125354     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.
Authors:
Evanthia Galanis; Wenting Wu; Jann Sarkaria; Susan M Chang; Howard Colman; Daniel Sargent; David A Reardon
Related Documents :
10587294 - Antitumor activity of mgi 114 (6-hydroxymethylacylfulvene, hmaf), a semisynthetic deriv...
15832424 - Combined effects of cantide and chemotherapeutic drugs on inhibition of tumor cells' gr...
23376424 - Expression of intercellular adhesion molecule-1 by hepatocellular carcinoma stem cells ...
21358264 - Validating the use of a luciferase labeled breast cancer cell line, mda435lcc6, as a me...
18985494 - Cytotoxic triterpenoid saponins from the roots of ardisia crenata.
8910274 - Melanoma cell expression of fas(apo-1/cd95) ligand: implications for tumor immune escape.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current oncology reports     Volume:  13     ISSN:  1534-6269     ISO Abbreviation:  Curr Oncol Rep     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-04     Completed Date:  2011-04-21     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  100888967     Medline TA:  Curr Oncol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  42-9     Citation Subset:  IM    
Affiliation:
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. galanis.evanthia@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Protocols
Brain Neoplasms / chemistry*,  genetics,  therapy*
Clinical Trials as Topic / methods*
Humans
Individualized Medicine / methods*
Molecular Biology / methods*
Research Design
Tumor Markers, Biological / analysis*
Grant Support
ID/Acronym/Agency:
CA-108961/CA/NCI NIH HHS; P50 CA108961/CA/NCI NIH HHS; P50 CA108961-02/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Tumor Markers, Biological
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of left ventricular myocardial ischemia and cardiac prognosis with cardiovascular mag...
Next Document:  Treatment option approaches to the management of chronic total occlusions.